Beyond Killing Germs: Phages and Microbial Functions Drive Next-Generation Medicine

For more than a century, the goal of antimicrobial therapy has been brutally simple: find the microbe causing the disease and eliminate it. Antibiotics have saved countless lives with this pathogen-centered logic, but their overuse has fueled antimicrobial resistance, disrupted beneficial microbiomes, and repeatedly failed against biofilm-protected and multidrug-resistant infections. A new review published in MicrobiologyOpen argues that medicine is now ready for a deeper shift, one that treats microbial communities not as lists of species to be eradicated but as functional systems whose activities, metabolites, and interactions can be measured, targeted, and deliberately reshaped.

The review, authored by Mohammad Nazrul Islam Bhuiyan and Maliha Momtaj, introduces what the authors call post-microbial therapeutics. The term does not describe a new drug class, and the authors are careful about that. Instead, it proposes an operational framework that links a therapeutic intervention to a defined microbial function, then to a measurable biochemical consequence, and finally to a validated host outcome. The sequence is explicit: clinical abnormality, candidate microbial function, candidate microbial module, experimental validation, intervention, perturbation, functional measurement, host-response validation, and clinical outcome. Anything less, the authors contend, is association rather than mechanism.

At the heart of the framework sits the concept of the microbial module: a functionally bounded unit of microorganisms that demonstrably contributes to a specified biological process and produces a measurable output. The authors draw a sharp line between computationally inferred candidate modules, identified through co-abundance, network connectivity, or predicted metabolic complementarity, and experimentally validated modules, which require perturbation, reconstruction, add-back experiments, isotope tracing, pathway-specific flux analysis, or metabolite rescue. Co-occurrence, they stress, is hypothesis-generating at best. A cluster of taxa that rise and fall together is not a therapeutic target until someone shows that its members actually perform the function in question and that disrupting them changes the output reproducibly.

Bacteriophages serve as the model perturbation throughout the review, and for good reason. Phage therapy predates the antibiotic era, faded in Western medicine after penicillin, and has roared back into prominence as the antimicrobial resistance crisis deepens. Contemporary phage therapy bears little resemblance to its early empirical use. Genome sequencing, receptor characterization, quantitative pharmacology, synthetic biology, and improved manufacturing now allow systematic assessment of phage identity, host range, safety, and suitability. Clinical studies and compassionate-use experience have reported encouraging safety and case-specific benefit against multidrug-resistant organisms, particularly in difficult-to-treat infections, although the evidence remains heterogeneous across species, patient populations, preparations, and endpoints.

The review is candid about why phage therapy remains incompletely standardized. Phage specificity, often celebrated as an ecological advantage, does not equal ecological predictability. Host range depends on receptor availability, bacterial physiological state, environmental conditions, and phage adaptation, and can vary dramatically among strains of the same species. Bacterial antiviral defenses, including CRISPR-Cas systems, restriction-modification mechanisms, receptor masking, and abortive infection, can block productive infection entirely. Phage pharmacology is unlike any conventional drug: therapeutic phages replicate in the presence of susceptible bacteria, making exposure and pharmacodynamic effect dynamically interdependent, while immune clearance, tissue barriers, and bacterial density complicate dosing. The authors propose the concept of an ecological dose, the magnitude and duration of perturbation needed to shift a defined microbial function, but they frame it strictly as a research hypothesis, not a validated clinical metric.

The distinction between phage modalities receives particular attention. Whole virulent phages are replicating biological agents whose activity depends on finding and lysing susceptible hosts. Lysins are nonreplicating enzymes that cleave peptidoglycan. Depolymerases degrade capsular or extracellular polysaccharides, potentially opening biofilm matrices. Engineered phages, including CRISPR-based programmable systems, add genomic and payload variables. These differences cascade into distinct pharmacology, manufacturing requirements, safety profiles, and regulatory pathways, and the authors argue that evidence for one modality cannot be generalized to another. Temperate phages, which can establish lysogeny and alter bacterial phenotype, fitness, and gene exchange, require especially cautious genomic screening for lysogeny-associated genes, virulence determinants, and resistance elements.

Across disease contexts, the review maps a graded evidence landscape. The strongest case remains targeted control of resistant pathogens. In biofilm-associated infections such as chronic osteomyelitis, diabetic wounds, and device-related disease, phage-based interventions may act at three levels: structural disruption, bacterial population control, and restoration of local function, but a reduction in biofilm biomass alone does not establish ecosystem restoration. In oncology and immunocompromised patients, where chemotherapy and antimicrobials can devastate colonization resistance, phages offer a potentially selective alternative, though altered immunity, mucosal injury, and neutropenia introduce additional uncertainty. In gastrointestinal and cardiometabolic disease, the most provocative findings emerge: selective phage targeting of high-alcohol-producing Klebsiella pneumoniae has been associated with improvement in nonalcoholic fatty liver disease-related phenotypes, and phage-antibiotic combinations have shown metabolically reorganized killing of multidrug-resistant K. pneumoniae. Yet the authors repeatedly caution that such associations do not prove that a defined module or metabolite mediates the clinical benefit.

Metabolites occupy the mechanistic middle ground of the framework. Short-chain fatty acids such as butyrate, tryptophan-derived indoles that activate the aryl hydrocarbon receptor, secondary bile acids, polyamines, and related compounds influence epithelial integrity, immune regulation, and systemic metabolism. Phage intervention can alter these pools through metabolic reprogramming before lysis, changed substrate competition and cross-feeding, or release of intracellular nutrients. The interactions run both ways: bacterial metabolic state and receptor expression shape phage susceptibility, while phage activity reshapes the chemical environment. The authors insist, however, that metabolites be treated as measurable functional intermediates requiring causal validation, not as assumed mediators of benefit, because diet, host metabolism, and microbial redundancy confound nearly every measurement.

The translational and governance implications are substantial. The review calls for product-specific regulation that distinguishes whole phages, engineered phages, lysins, depolymerases, and combination products, each with its own requirements for identity, potency, genomic safety, stability, and post-treatment surveillance. It urges integration of biofilm-aware susceptibility testing, bacterial antiviral-defense profiling, resistance surveillance, and standardized pharmacokinetics and pharmacodynamics into clinical workflows. Ethically, the authors warn that personalized phage matching, sequencing, and metabolomics could concentrate advanced therapy in specialized centers, widening health disparities unless standardized libraries, scalable manufacturing, and simplified workflows accompany the science. Compassionate-use successes, they note, should never be mistaken for proof of efficacy.

The review closes with a research agenda that reads as a checklist for the coming decade: causal validation linking defined phage perturbation to microbial function, metabolite change, and host outcome; systematic defense profiling; modality-specific comparisons; validated functional biomarkers; ecological pharmacology; and long-term monitoring of nontarget microbial functions. Computational tools, including machine learning and eventual digital-twin models, may support host-range prediction and module identification, but the authors insist they remain investigational and cannot replace phenotypic testing. The verdict is measured but ambitious: post-microbial therapeutics will earn their place in medicine not through the novelty of their terminology, but by whether they genuinely improve the prediction, testing, and reproducibility of microbiome-directed interventions, moving the field from describing ecosystems to engineering them with causal precision.

Subject of Research: Phage-based post-microbial therapeutics linking microbial modules, metabolites, and host outcomes

Article Title: Post‐Microbial Therapeutics for the Next Generation of Medicine

Article References: Bhuiyan, M. N. I., & Momtaj, M. (2026). Post‐Microbial Therapeutics for the Next Generation of Medicine. MicrobiologyOpen, 15(5), Article e70427. https://doi.org/10.1002/mbo3.70427

Image Credits: AI Generated

DOI: 10.1002/mbo3.70427

Keywords: bacteriophage therapy, antimicrobial resistance, microbiome, microbial metabolites, phage engineering, biofilms, microbial modules, pharmacokinetics, synthetic biology, CRISPR, ecological dose, clinical translation